Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally poached its employees and stole trade secrets when developing the ...

Wells Fargo raised the firm’s price target on Masimo (MASI) to $171 from $160 and keeps an Overweight rating on the shares following ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings Conference Call. The company's press release is available at www.masimo.com. At this time, all lines have ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...

IRVINE, California - Masimo (NASDAQ:MASI) Corporation (NASDAQ:MASI) reported third-quarter earnings that beat analyst expectations, but its shares tumbled 7.5% as fourth-quarter revenue guidance ...

The protracted legal wrangling between Apple and health wearable company Masimo has resulted in a nominal win for the tech giant – but failed to achieve its objectives. Apple and Masimo have ...